Clinical Trials

  1. Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang 4/11/2024

    In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants.

  2. Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge 9/25/2024

    Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa.

  3. A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino 9/11/2024

    Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery.

  4. Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki 12/22/2025

    In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA).

  5. Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts 8/29/2024

    Cell & Gene: The Podcast Host, Erin Harris, welcomes Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, for an in-depth interview about existing issues with current CAR T approaches, "auto versus allo," and why allogeneic is the path forward. They also discuss how and why allogeneic therapies are truly scalable.

  6. Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan 3/28/2024

    Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.

  7. The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault 7/18/2023

    Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as how the CGT sector is benefiting from RNA, AI, and synthetic biology.

  8. Inside Sanofi's Genomic Medicine Vision with Mike Quigley, Ph.D. 9/24/2025

    On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access.

  9. Navigating The Journey To Safer Stem Cell Therapies With Orca Bio's Nate Fernhoff 7/29/2025

    Cell & Gene: The Podcast Host, Erin Harris, talks to Orca Bio CEO and Co-Founder Nathaniel Fernhoff as he recounts the company’s origins and evolution, tracing its roots to pioneering stem cell research at Stanford University and Dr. Irv Weissman's lab.

  10. CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant 5/9/2024

    On this episode of Cell & Gene: The Podcast, Addimmune CMO, Dr. Marcus Conant, shares the why behind cell and gene therapy to treat HIV, and he explains the company's lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.